Brokerages expect that Intellia Therapeutics Inc (NASDAQ:NTLA) will report earnings of ($0.53) per share for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Intellia Therapeutics’ earnings, with estimates ranging from ($0.64) to ($0.47). Intellia Therapeutics posted earnings of ($0.43) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 23.3%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, February 26th.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.
On average, analysts expect that Intellia Therapeutics will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($2.31) to ($1.97). For the next year, analysts anticipate that the company will post earnings of ($2.28) per share, with EPS estimates ranging from ($3.00) to ($1.71). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings results on Thursday, October 31st. The company reported ($0.49) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.12. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company had revenue of $10.60 million for the quarter, compared to analyst estimates of $9.17 million. During the same period in the previous year, the company posted ($0.53) earnings per share. The firm’s revenue was up 43.2% on a year-over-year basis.
A number of analysts recently commented on NTLA shares. Raymond James upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating and set a $24.00 price objective for the company in a research report on Friday, November 1st. Chardan Capital set a $57.50 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Friday, September 27th. BidaskClub upgraded Intellia Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 2nd. Zacks Investment Research upgraded Intellia Therapeutics from a “hold” rating to a “strong-buy” rating and set a $15.00 price objective for the company in a research report on Wednesday. Finally, ValuEngine cut Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $24.94.
Shares of NASDAQ NTLA traded up $0.22 during mid-day trading on Thursday, hitting $13.15. 558,600 shares of the stock traded hands, compared to its average volume of 559,375. The company has a market cap of $625.20 million, a price-to-earnings ratio of -6.64 and a beta of 2.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 7.89 and a current ratio of 7.89. Intellia Therapeutics has a 52 week low of $10.26 and a 52 week high of $19.38. The stock has a fifty day moving average price of $12.21 and a 200-day moving average price of $14.87.
A number of institutional investors and hedge funds have recently modified their holdings of NTLA. Benjamin Edwards Inc. increased its position in Intellia Therapeutics by 60.9% in the second quarter. Benjamin Edwards Inc. now owns 1,691 shares of the company’s stock worth $28,000 after buying an additional 640 shares in the last quarter. Bank of Montreal Can increased its position in Intellia Therapeutics by 406.5% in the second quarter. Bank of Montreal Can now owns 3,824 shares of the company’s stock worth $63,000 after buying an additional 3,069 shares in the last quarter. Mizuho Securities Co. Ltd. purchased a new stake in Intellia Therapeutics in the second quarter worth about $64,000. Aperio Group LLC purchased a new stake in Intellia Therapeutics in the second quarter worth about $83,000. Finally, Resources Investment Advisors LLC. increased its position in Intellia Therapeutics by 60.2% in the second quarter. Resources Investment Advisors LLC. now owns 8,648 shares of the company’s stock worth $142,000 after buying an additional 3,250 shares in the last quarter. Institutional investors and hedge funds own 83.61% of the company’s stock.
About Intellia Therapeutics
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.
See Also: After-Hours Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com